Haleon nabs finance chief from Tate & Lyle as CFO steps down
The chief financial officer of consumer health company
(HLN ) is to step down after three years and will be replaced by Tate & Lyle's CFO Dawn Allen.The company, known for brands like Sensodyne, Centrum and Panadol, announced on Wednesday that Tobias Hestler has decided to leave "to better balance work demands with the management of a long-term health condition".
He will leave the company in November, having served nearly three years after joining in December 2021.
Hestler will be succeeded by Dawn Allen, the current CFO at Tate & Lyle and former CFO at Mars Inc, who also serves on the board at ITV.
Allen, who will receive an annual salary of £730,000 along with an annual bonus and long-term incentive plans, has "extensive consumer and international experience and will be a great addition to our executive team", said Haleon's chief executive Brian McNamara.
Allen said she was "very excited" to join Haleon. "Its clear purpose and fascinating journey through separation and beyond sets a strong foundation for the future. I am looking forward to help shape the next phase of the journey," she said.
In a separate statement, ingredients group Tate & Lyle said: "The board has begun a process to appoint a successor to Mrs Allen and a further announcement will be made in due course."
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.